8-K: Autolus Therapeutics Presents Promising Long-Term Data for Obe-cel in Adult Leukemia at ASCO

Autolus Therapeutics announced encouraging long-term follow-up data from the FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia (ALL), showing durable responses and potential for a survival plateau.

Summary

• Autolus Therapeutics presented updated data from the Phase 1b/2 FELIX study of obe-cel for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia (ALL) at the 2024 ASCO Annual Meeting.
• The study showed that 78% of patients who received obe-cel achieved an overall response (CR/CRi).
• At a median follow-up of 21.45 months, 40% of responding patients were in ongoing remission without needing a stem cell transplant (SCT) or other therapy.
• The median event-free survival (EFS) was 11.9 months, and the median overall survival (OS) was 23.8 months.
• The estimated 12-month EFS and OS rates were 49.5% and 61.1%, respectively.
• The data suggests that ongoing CAR T cell persistence is associated with improved event-free survival.
• Consolidative stem cell transplants did not appear to improve EFS or OS in patients who responded to obe-cel.
• Patients who lost CAR T persistence had a 2.7 fold increased risk of relapse or death compared to patients with ongoing CAR T persistence.
• Patients who experienced B-cell recovery had a 1.7 fold increased risk of relapse or death compared with patients without B-cell recovery.
• The results of the FELIX trial have been submitted to the FDA as part of a BLA, with a PDUFA target action date of November 16, 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data for obe-cel, with strong response rates and encouraging long-term outcomes. The lack of benefit from consolidative SCT is also a positive finding, as it simplifies treatment. The company's strong cash position further supports a positive outlook.

Positives

• Obe-cel demonstrates a high overall response rate of 78% in a difficult-to-treat patient population.
• A significant proportion of patients, 40%, achieved durable remission without needing further interventions like stem cell transplants.
• The data suggests a potential for a long-term survival plateau with obe-cel treatment.
• Ongoing CAR T cell persistence is a strong indicator of improved event-free survival.
• The treatment was generally well tolerated with low rates of high-grade CRS and ICANS.
• The company has a strong cash position of $759M at the end of Q1 2024, which fully funds the obe-cel launch in adult ALL and allows for autoimmune program acceleration.

Negatives

• A significant portion of patients, 36%, relapsed or died during the study.
• Consolidative stem cell transplants did not improve outcomes for patients who responded to obe-cel.
• Loss of CAR T persistence and B-cell recovery were associated with increased risk of relapse or death.
• Two deaths were considered treatment-related per investigator assessment.

Risks

• The risk that clinical programs do not advance or result in approved products on a timely or cost-effective basis.
• The results of early clinical trials are not always predictive of future results.
• The cost, timing, and results of clinical trials are uncertain.
• Many product candidates do not become approved drugs on a timely or cost-effective basis or at all.
• There are risks associated with the ability to enroll patients in clinical trials.
• Possible safety and efficacy concerns could arise during the development process.

Future Outlook

Autolus anticipates several milestones, including further data updates at EHA and ASH in 2024, a Marketing Authorization Application to MHRA in the second half of 2024, and initial data from the SLE Phase 1 study in late 2024.

Management Comments

• Dr. Christian Itin, CEO of Autolus, stated that they are pleased to observe the potential for a long-term plateau of survival outcomes with obe-cel in the FELIX trial.
• Dr. Itin also noted that 40% of patients are in ongoing remission without Stem Cell Transplant (SCT) or other therapy, and they continue to see evidence that ongoing CAR T persistence is associated with this event-free survival.

Industry Context

This announcement is significant in the CAR T therapy space, as it provides further evidence of the potential for long-term durable responses in patients with relapsed/refractory B-cell ALL. The data also suggests that obe-cel may offer a more effective treatment option compared to existing therapies, particularly given the lack of benefit from consolidative stem cell transplants.

Comparison to Industry Standards

• The 78% overall response rate (CR/CRi) observed in the FELIX trial is competitive with other CAR T therapies for relapsed/refractory B-cell ALL, such as Novartis' Kymriah and Gilead's Yescarta.
• The 40% ongoing remission rate without subsequent SCT or other therapy at 21.45 months median follow-up is a notable result, suggesting a potential for long-term disease control.
• The median EFS of 11.9 months and median OS of 23.8 months are also encouraging, although direct comparisons with other CAR T therapies are difficult due to differences in trial design and patient populations.
• The observation that consolidative SCT did not improve outcomes is important, as it suggests that obe-cel may be effective as a standalone therapy, potentially reducing the need for additional interventions.
• The data on CAR T persistence and its correlation with improved EFS is consistent with findings from other CAR T studies, highlighting the importance of long-term T cell activity for durable responses.

Stakeholder Impact

• Shareholders will likely view the positive clinical data favorably, potentially leading to an increase in share price.
• Patients with relapsed/refractory B-cell ALL may have a new and effective treatment option.
• Employees of Autolus will be encouraged by the progress of the obe-cel program.
• The positive results may strengthen Autolus' position in the biopharmaceutical industry.

Next Steps

• Autolus plans to present further data updates at EHA and ASH in 2024.
• The company is working towards a Marketing Authorization Application to MHRA in the second half of 2024.
• The FDA PDUFA target action date is November 16, 2024.
• Initial data from the SLE Phase 1 study is expected in late 2024.

Key Dates

Keywords

obe-cel, CAR T therapy, B-cell ALL, leukemia, relapsed/refractory, ASCO, event-free survival, overall survival, stem cell transplant, FDA, PDUFA